The Cost of Irreproducible Research

Half of basic science studies cannot be replicated, according to a new analysis—to the tune of $28 billion a year in the U.S.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

PIXABAY, OPENCLIPARTVECTORSJust about half of all basic life science research is flawed to the point that it cannot be replicated, according to an analysis published in PLOS Biology yesterday (June 9). These “irreproducible” studies end up costing around $28 billion annually in the U.S.

“While false positives are an inevitable part of scientific research, our study shows that the current level of irreproducibility in preclinical research is very costly,” study coauthor Timothy Simcoe, an economist at the US Council of Economic Advisors, said in a press release.

The analysts used previous estimates of irreproducibility to arrive at their number. Poor quality reagents and materials were the biggest cause of flaws in experiments, mucking up more than one third of preclinical studies, the team found. Poor study design and insufficient analysis or reporting each afflicted a little more than a quarter of studies, while improper laboratory protocols took down one out of every 10 studies. “The four categories are decent, but the estimates are off,” John Ioannidis, a Stanford University ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies